Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma (Q36687470)

15 August 2017

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma (English)

1 reference

15 August 2017

1 reference

8

1 reference

15 August 2017

Antonio Maria Grimaldi

6

0 references

Corrado Caracò

Corrado Caracò

7

0 references

Secondo Lastoria

Secondo Lastoria

12

0 references

Antonella Petrillo

Antonella Petrillo

11

0 references

Gerardo Botti

10

Gerardo Botti

1 reference

15 August 2017

Paolo Antonio Ascierto

18

Paolo Antonio Ascierto

1 reference

15 August 2017

5

Ester Simeone

1 reference

15 August 2017

15

Nicola Mozzillo

1 reference

15 August 2017

13

Ernesta Cavalcanti

1 reference

15 August 2017

Antonio Daponte-Codina

1

Antonio Daponte

1 reference

Antonio Giuseppe Maria Cossu

15 August 2017

9

Antonio Cossu

1 reference

15 August 2017

17

Giuseppe Comella

1 reference

15 August 2017

16

Ciro Gallo

1 reference

15 August 2017

14

Pasquale Aprea

1 reference

15 August 2017

4

Bruno Massidda

1 reference

15 August 2017

3

Luigi Maiorino

1 reference

15 August 2017

Simona Signoriello

2

1 reference

15 August 2017

Southern Italy Cooperative Oncology Group (SICOG)

19

1 reference

15 August 2017

13 February 2013

1 reference

Journal of Translational Medicine

15 August 2017

1 reference

15 August 2017

11

1 reference

15 August 2017

38

1 reference

https://scigraph.springernature.com/pub.10.1186/1479-5876-11-38

15 August 2017

0 references

cites work

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Cancer treatment and survivorship statistics, 2012

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Melanoma: a model for testing new agents in combination therapies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Adjuvant therapy of melanoma with interferon: lessons of the past decade

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Fotemustine in the treatment of brain primary tumors and metastases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3598549

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23402397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23402397

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1479-5876-11-38

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference